Kornimate/medical-research-clean huggingface dataset:
pelvic angiography in non-responders to phosphodiesterase-5 inhibitors (panpi)

Conditions: Erectile Dysfunction

Summary: the specific aim of this pilot study is to describe the angiographic prevalence and pattern of internal pudendal artery (and associated inflow vessel) atherosclerosis in patients with erectile dysfunction who are non-responsive to pde-5 inhibitors (i.e., viagra) who are referred for clinically-indicated cardiac catheterization.

the specific aim of this study is to determine if the deep penile arteries can be seen angiographically from the iliac arteries to delineate penile vasculature. significant obstructive atherosclerotic disease of the deep penile arteries may be present in impotent males. the etiology of erectile dysfunction is multifactorial and may involve vascular disease, endocrine disorders, neurologic disease, prescription medications, psychological issues and/or trauma in any given patient. vascular disease in patients with erectile dysfunction may be due to trauma, congenital anomalies, or atherosclerosis.

Eligibility criteria:
inclusion criteria: * male patients * at least 50 years * erectile dysfunction * dissatisfaction with their use of a phosphodiesterase-5 inhibitor * coronary artery disease (or at risk for coronary artery disease) * undergoing diagnostic cardiac catheterization or patients with peripheral vascular disease undergoing peripheral arteriography exclusion criteria: * patients who respond favorably to phosphodiesterase-5 inhibitors * known non-vascular etiologies of their erectile dysfunction * probable neurogenic erectile dysfunction due to radiation injury, surgery, or transurethral resection of the prostate * calculated gfr \< 60 ml/min/1.73 m2 will also be excluded * disease that necessitates complex percutaneous intervention will be excluded per the investigators discretion

Keywords: ed erectile dysfunction
volar locked plating vs bridging external fixation in distal radius fracture

Conditions: Distal Radius Fracture

Summary: the purpose of this study is to evaluate function, pain and radiographic evaluation in patients treated with volar locked plating versus hoffman ii bridging external fixation in patients with extraarticular distal radius fractures, ao/ota type a

we have designed a randomized prospective study for comparison of volar locked plating versus hoffman ii bridging external fixation in patients with extraarticular dislocated distal radius fractures ao/ota type a3. on the basis of power analysis a total of 160 patients are to be included in this project. the follow-up period is 1 year and evaluation is based on x-ray analysis, grip strength, range of motion, pain and satisfaction with the treatment ( prwe, quick-dash)

Eligibility criteria:
inclusion criteria: * patients with dislocated extraarticular distal radius fracture age 18-70 years exclusion criteria: * cognitively impaired * drug abuse * congenital bone disease * earlier wrist injury * open fracture, gustilo-anderson type 3 * pathological fractures( except osteoporotic fractures) * tourists

Keywords: distal radius fracture
global coagulation assessment in cirrhosis and aclf

Conditions: Acute-On-Chronic Liver Failure; Cirrhosis, Liver

Summary: background: patients with cirrhosis and acute-on-chronic liver failure (aclf) may have bleeding complications which can lead to increased mortality. standard coagulation tests (scts) like prothrombin time, platelet count and activated partial thromboplastin do not accurately depict in vivo coagulation profile. point-of-care viscoelastic coagulation testing devices like thrombo-elastography (teg) and sonoclot may be better for guiding patient management. methods: this prospective observational study compared and validated the point of care (poc) tests and scts in 70, 72 and 25 persons with aclf, decompensated cirrhosis and healthy controls respectively.


Eligibility criteria:
inclusion criteria: * all patients with acute on chronic liver failure * all patients with cirrhosis of liver exclusion criteria: * recent blood or blood component transfusion in last 2 weeks * hiv infection * antiplatelet, anticoagulant or antifibrinolytic therapy * patients on dialysis * pregnant females * active malignancy in last 5 years * chronic heart failure * chronic pulmonary disease * end stage renal disease

Keywords: sonoclot thromboelastography rotem
effects of pelvic belt and kinesio tape on pain and functional mobility in pregnancy-related pelvic girdle pain

Conditions: Pelvic Girdle Pain

Summary: this study investigates the effects of pelvic belt (pb) and kinesio taping (kt) applications on pain and functional mobility in pregnancy-related pelvic girdle pain (pgp), in comparison with the control group that received only pain neuroscience education and ergonomic training.

although there is strong evidence in the literature that pelvic support belts reduce pain in pregnancy-related pelvic girdle pain, no study investigating its effect on functional mobility with performance-based measurement methods or investigating its effectiveness on kinesiophobia has been found. studies investigating the efficacy of kt in pregnant women with pgp are few and many are methodologically weak studies, most of which do not contain randomization and control groups. also, no study has been found in the literature, which compares the effectiveness of pb and kt in pregnant women with pgp. therefore, the primary aim of this study is to examine the effects of pb and kt on pain and functional mobility in pregnant women with pgp in comparison with the control group, which is only given pain neuroscience education and ergonomic training. the secondary aims are to investigate the effects of these applications on kinesiophobia, activity limitation and sleep quality; and to compare the groups in regard to patient compliance and treatment satisfaction levels of the groups.

Eligibility criteria:
inclusion criteria: * being able to read and write in turkish * being in 2nd or 3rd trimester of pregnancy * having pgp for more than one week * signing the informed consent form for the study exclusion criteria: * visual, auditory or cognitive problems which may prevent participation to the study * health problems other than pregnancy-related pgp (orthopedic, neurologic, cardiorespiratory, etc.) or trauma history, which may affect standing from sitting, walking or stair climbing activities * any gynecological or urological problems which may mimic pregnancy related pgp * any diagnosed pregnancy complications other than pgp (preeclampsy, hypertension, diabetes,placental/fetal anomaly, preterm labor, etc.) * high risk pregnancy (multiple gestation, etc.) * history of spinal injury, ankylosing spondilitis, rheumatoid arthritis, intervertebral disc pathology) * a positive straight leg raise test result, as well as sensory or motor deficits indicating intervertebral disc pathology * history of prepregnancy low back or pelvic girdle pain * using any analgesic or myorelaxant medication * contraindications to kt or pb (impaired skin integrity or lesion in the lumbopelvic and abdominal regions, history of allergic reaction, etc.) * previous kt (abdominal or lumbosacral) or pb experience

Keywords: kinesio tape pelvic belt functional mobility pain kinesiophobia neuroscience education ergonomic education activity limitation
microbial soy milk consumption, inflammation and renal function among type 2 diabetic patients with nephropathy

Conditions: Type II Diabetic Patients With Nephropathy

Summary: the aim of the present study was to determine the effects of fortified soy milk with l. planetarium a7 on a cytokine receptor, an adipokine and renal function biomarkers in type ii diabetic patients with nephropathy.


Eligibility criteria:
inclusion criteria: * adults * type 2 diabetic patients with stages 1 and 2 of nephropathy (defined as meeting criteria including fasting blood glucose \>126 mg/dl, hypoglycemic agents, or insulin intake, proteinuria \>300 mg/day, and glomerular filtration rate \>90 ml/min) exclusion criteria: * pregnancy or lactating in women * allergy or intolerance to soy milk or avoidance of soy milk consumption * smoking, alcoholism * recent antibiotic therapy and using of supplements containing vitamins and minerals * any medical condition such as inflammatory bowel disease, infection, liver disease and rheumatoid arthritis.
acupuncture lowering blood pressure for secondary prevention of stroke

Conditions: Cerebral Infarction

Summary: this study evaluate the effects of acupuncture method on the recurrence of ischemic stroke patients.half of participants will receive "huo xue san feng" acupuncture combining 1 antihypertensive medication on the routine ischemic stroke treatments' basis. while the other half will receive 1 antihypertensive medication and basic treatments for ischemic stroke.

under recuiting 480 patients come from 5 hospitals in china.eligible patients will be randomly assigned into 2 groups: treatment group and control group. the treatment group will receive "huo xue san feng" acupuncture combining 1 antihypertensive medication on the routine ischemic stroke treatments' basis. the control group will receive 1 antihypertensive medication and basic treatments for ischemic stroke. "huo xue san feng" acupuncture will be given six sessions weekly for the first 6 weeks and three times weekly for the next 6 weeks. a 9-month follow-up will thereafter be conducted. antihypertensive medications will be adjusted based on bp levels.

Eligibility criteria:
inclusion criteria: * patients with the first time ischemic stroke * patients meet the tcm diagnosis standard of stroke * patients meet the diagnosis standard of hypertension, taking only 1 type of antihypertensive drugs for at least 2 weeks before admission,corresponding to systolic pressure ranging from 140 to 160mmhg and diastolic ranging from 90-100mmhg. * the course of ischemic stroke ranging from 2 weeks to 6 weeks . * men or women aged between 35 and 70 years old. * patients who are willing to participate in our clinical trial agree to sign the informed consent form. exclusion criteria: * patients who have been diagnosed with secondary hypertension. * patients have taken beta blockers or diuretics or non dihydropyridine calcium channel blocker （ndhp-ccb）for a long time because of cardiovascular disease. * patients who taking 1 type of antihypertensive drugs,blood pressure under 140/90mmhg. * patients accompanied with other neurological disorders,such as epilepsy, peripheral nerve injury, * patients accompanied with severe medical condition such as severe hematopoietic system disease, coagulation dysfunction and malignant tumor. * patients accompanied with diabetic nephropathy,severe liver and renal insufficiency,severe cardiac or pulmonary dysfunction,severe arrhythmia. * patients who have occured skin infections near the acupoint location. * pregnant or breast-feeding women. * patients who currently participate in another clinical trial.

Keywords: acupuncture hypertension second prevention of stroke efficacy rct study protocol
quetiapine fumarate bipolar maintenance monotherapy

Conditions: Bipolar Disorder

Summary: this is a multicenter, randomized, parallel-group, double-blind, placebo-controlled study to evaluate the efficacy and safety of quetiapine and lithium (comparator in the study) for up to 104 weeks of maintenance treatment in adult patients with bipolar i disorder. please note: seroquel sr and seroquel xr refer to the same formulation. the sr designation was changed to xr after consultation with fda.


Eligibility criteria:
inclusion criteria: * signed informed consent * 18 years or older * a diagnosis of bipolar i disorder * have a current manic, depressed or mixed episode * have had a manic, depressed or mixed episode during the last 26 weeks that was treated with quetiapine * female patients of childbearing potential must be using a reliable method of contraception exclusion criteria: * pregnancy * substance or alcohol dependence at enrollment * unstable thyroid function * unstable diabetes * unstable or inadequately treated medical illness e.g., angina pectoris and hypertension * use of an experimental drug within 30 days of enrollment

Keywords: bipolar i disorder.
study evaluating sc291 in subjects with r/r b-cell malignancies (ardent)

Conditions: Non Hodgkin Lymphoma; Chronic Lymphocytic Leukemia

Summary: sc291-101 is a phase 1 study to evaluate sc291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

this is an open-label, single arm, phase 1, first-in-human (fih) study to evaluate the safety and tolerability of sc291 administered intravenously (iv) following a standard lymphodepleting chemotherapy regimen of cyclophosphamide and fludarabine in subjects with nhl or cll who have received two or more prior systemic treatments per standard of care (or after autologous stem cell transplant \[asct\] for nhl). this study will be conducted in 2 parts. phase 1a: dose finding using a 3+3 design in subjects with nhl or cll. phase 1b: dose expansion to further evaluate safety and efficacy at the rp2d in subjects with lbcl and cll.

Eligibility criteria:
inclusion criteria: * male or female subjects aged 18-80 years at the time of signing informed consent. * diagnosis of nhl (who 2016 criteria) or cll (iwcll criteria), including: * large b-cell lymphoma, including diffuse large b-cell lymphoma (dlbcl) not otherwise - - specified (including dlbcl arising from indolent lymphoma), primary mediastinal large -- - b-cell lymphoma, high grade b-cell lymphoma, follicular lymphoma grade 3b * follicular lymphoma (dose escalation only except for follicular lymphoma grade 3b) * marginal zone lymphoma (dose escalation only) * mantle cell lymphoma (dose escalation only) * cll or sll * relapsed/refractory disease after at least 2 prior systemic regimens per standard of care or after autologous stem cell transplant * ecog performance status of 0 or 1. * at least one measurable lesion per lugano classification (nhl); cll subjects must meet iwcll treatment criteria * life expectancy ≥12 weeks exclusion criteria: * prior anti-cd19 therapy including cd19-directed car t treatment or other cd19-directed antibody or cell therapy (e.g., nk cell). (part 2 dose expansion only - prior approved cd19-directed car t therapy required) * history of primary central nervous system (cns) lymphoma or presence of cns metastases * systemic anticancer therapy (including platinum-based chemotherapies and i/o therapies) or radiotherapy within 14 days of sc291 (28 days for biologics) * autologous hsct within 6 weeks of treatment with sc291 (or allogeneic hsct at any time). * active autoimmune disease or any other diseases requiring immunosuppressive therapy or corticosteroid therapy (defined as \>20 mg/day prednisone or equivalent). * history or presence of cardiac or cns disorders as defined in the protocol

Keywords: large b cell lymphoma car t cell therapy mantle cell lymphoma indolent follicular lymphoma marginal zone lymphoma high-grade b cell lymphoma primary mediastinal b cell lymphoma diffuse large b cell lymphoma non-hodgkin's lymphoma chronic lymphocytic leukemia allogeneic hypoimmune cd19
documentation of in-flight medical emergencies with medical incident report forms.

Conditions: In-flight Medical Emergency

Summary: the purpose of this study is to perform a descriptive, content-based analysis on the different forms of documentation for in-flight medical emergencies that are currently provided in the emergency medical kits on board commercial airlines.


Eligibility criteria:
inclusion criteria: * medical incident report form exclusion criteria: * no medical incident report form
the cervix as a natural tamponade in postpartum hemorrhage caused by placenta previa and placenta previa accreta

Conditions: Placenta Previa; Placenta Previa Accreta

Summary: placenta previa and placenta accrete carry significant maternal and fetal morbidity and mortality. several techniques have been described in the literature for controlling massive bleeding associated with placenta previa cesarean sections. the aim of this study is to evaluate the efficacy and safety of the use of the cervix as a natural tamponade in controlling postpartum hemorrhage caused by placenta previa and placenta previa accreta.

background: placenta previa and placenta accrete carry significant maternal and fetal morbidity and mortality. the maternal mortality in women with placenta accreta may reach as high as 7-10%. several techniques have been described in the literature for controlling massive bleeding associated with placenta previa cesarean sections, including uterine packing with gauze, balloon tamponades, the b-lynch suture, insertion of parallel vertical compression sutures, a square suturing technique and embolization or ligation of the uterine and internal iliac arteries, but there is a wide variation in the success rate of these maneuvers. in a case report, dawlatly et al. (2007) described a simple technique of suturing an inverted lip of the cervix over the bleeding placental bed that was successful in controlling the bleeding, saving the patient's life, and preserving her uterus. the objective of this trial is to evaluate the safety and efficacy of the use of this dawlatly stitch as a natural tamponade for controlling postpartum haemorrhage in cases of placenta previa and/ or placenta previa accreta.

Eligibility criteria:
inclusion criteria: 1. all participating women had one or more previous cesarean deliveries. 2. were diagnosed with placenta previa and/ or placenta previa accreta by ultrasound. when the ultrasound result was not conclusive for placenta accreta, mri was performed. 3. all participating women desired to preserve their fertility 4. patients with focal (partial) placenta previa accreta/ placenta previa. exclusion criteria: 1. placenta percreta. 2. diffuse placenta accreta or increta. 3. uncontrollable postpartum hemorrhage.
comparison of nylon flocked swabs and saline aspirates for detection respiratory viruses

Conditions: Respiratory Syncytial Virus; Human Metapneumovirus; Influenza; Bronchiolitis; Pediatric

Summary: collection of nasal secretions from infants and toddlers for viral testing is usually done using the nasal washing technique described by hall in 1975. this is cumbersome. previous attempts to use swabs have been unsuccessful because the swabs didn't work well. a newly designed swab may work better and in this study we compare the new swab with the old style nasal washing. .

collection of nasal secretions from infants and toddlers for viral testing is typically performed using the nasal saline aspirate technique described by hall in 1975. nylon flocked swabs (nfs) and universal transport medium for room temperature (utm-rt) (copan medical, murrieta, ca) storage media have been found to be an effective collection and transport method for bacteria causing sexually transmitted infections. we adapted these swabs and storage medium to collect respiratory viruses from children less than18 months old and compared detection rates using nfs and traditional nasal aspirates. we will determine the relative roles of the utm-rt and nfs release and therefore measured viral detection rates of common respiratory pathogens in traditional saline aspirates stored in utm-rt. our primary hypothesis is that nasal secretions collection using nfs stored in utm-rt will lead to a higher detection rate of the respiratory viruses we arestudying; namely rsv, influenza and human metapneumovirus from than collection of unpreserved saline nasal aspirates in children less than 18 months of age.

Eligibility criteria:
inclusion criteria: * treating clinican ordered rsv antigen testing exclusion criteria: * refusal of consent * age \> 18 months

Keywords: respiratory syncytial virus bronchiolitis pediatric
platelet rich plasma vs platelet fibrin plasma in treatment of diabetes related wound：a randomized controlled trial

Conditions: Diabetic Foot

Summary: the goal of this randomized control trial is to compare the efficacy and safety of platelet rich plasma vs platelet fibrin plasma in patients with diabetes foot ulcer. the main question it aims to answer are: * whether the platelet fibrin plasma have noninferior efficacy than platelet rich plasma in treatment of diabetes foot ulcer？ * whether the platelet fibrin plasma have noninferior safety than platelet rich plasma in treatment of diabetes foot ulcer？ participants will be assigned with a 1:1 ratio into intervention group and control group. participants of intervention group will receive platelet fibrin plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure. participants of intervention group will receive platelet rich plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.


Eligibility criteria:
inclusion criteria: 1. the patient is aged 18-80 years old; 2. diagnosed as type 1 or type 2 diabetes according to the world health organization standard, blood sugar has been controlled before enrollment, and the level of glycated hemoglobin hba1c is less than 10%; 3. diabetes wounds with poor healing or prolonged healing need standard wound treatment; 4. there is no disseminated infection or the disseminated infection has been controlled; 5. after preparing the wound bed, the condition for using platelet plasma to close the wound is met; 6. voluntarily sign an informed consent form; exclusion criteria: 1. severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, and respiratory failure have not been corrected yet; 2. severe ischemia of the wound surface, unable to seek medical attention or not yet corrected; 3. uncontrolled systemic or disseminated infections; 4. blood glucose is out of control or not yet effectively controlled; 5. blood system diseases with uncorrected coagulation dysfunction or platelet dysfunction; 6. there is active bleeding inside the wound, and routine basic treatment plans cannot be implemented; 7. platelets ≤ 80 × 10\^9, hemoglobin\<90g/l; 8. patients with advanced malignant tumors; 9. active period of autoimmune diseases; 10. the patient is unable to cooperate or has mental disorders; 11. according to the judgment of the researchers, the patient has a clear and irremovable cause that affects wound healing, which is not suitable for this study or cannot comply with the requirements of this study.

Keywords: diabetes foot ulcer platelet rich plasma platelet fibrin plasma